Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study

MLA

Rachel O’Connell, et al. “Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study.” The Oncologist, vol. 18, Oct. 2013, pp. 1221–28. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....86acba69a6bf739f32a5c7cf3085c89c&authtype=sso&custid=ns315887.

APA

Rachel O’Connell, J Martyn, Martin R. Stockler, Madeleine King, Merryn Voysey, Kim Gillies, Phyllis Butow, M. Friedlander, Katrin Marie Sjoquist, & Amit M. Oza. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study. The Oncologist, 18, 1221–1228.

Chicago

Rachel O’Connell, J Martyn, Martin R. Stockler, Madeleine King, Merryn Voysey, Kim Gillies, Phyllis Butow, M. Friedlander, Katrin Marie Sjoquist, and Amit M. Oza. 2013. “Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study.” The Oncologist 18 (October): 1221–28. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....86acba69a6bf739f32a5c7cf3085c89c&authtype=sso&custid=ns315887.